Posted On: 10/26/2015 3:05:15 PM
Post# of 72446
This is still only about 158 million market cap, 3 drugs with 4 clinical trials and clearly more clinical trials on the way.
AVXLD, 256 million market cap, 1 drug in one Phase 2A trial in AUSTRALIA not U.S. (and in the extremely risky Alzheimers area). [Disclaimer: I own AVXLD and have big profits -- not badmouthing the stock.]
GALE, 272 million market cap, terrible management, all kinds of problems with their drug and trials.
SYN 206 million market cap, terrible management did a secondary offering at 2/3 of the then current stock price. Possibly good drugs, I have owned it and probably will again.
AXON, 1.2 Billion (yes, Billion with a
market cap. Tiny staff, no clinical trials, the one drug they are supposedly developing already failed its clinical trial -- was sold to AXON for 5 million. Unlike CTIX, they did not get a whole new class of antibiotics for their 5 million.
AVXLD, 256 million market cap, 1 drug in one Phase 2A trial in AUSTRALIA not U.S. (and in the extremely risky Alzheimers area). [Disclaimer: I own AVXLD and have big profits -- not badmouthing the stock.]
GALE, 272 million market cap, terrible management, all kinds of problems with their drug and trials.
SYN 206 million market cap, terrible management did a secondary offering at 2/3 of the then current stock price. Possibly good drugs, I have owned it and probably will again.
AXON, 1.2 Billion (yes, Billion with a
market cap. Tiny staff, no clinical trials, the one drug they are supposedly developing already failed its clinical trial -- was sold to AXON for 5 million. Unlike CTIX, they did not get a whole new class of antibiotics for their 5 million.
(0)
(0)
